STOCK TITAN

NeuroOne Medical Technologies Corporation - NMTC STOCK NEWS

Welcome to our dedicated page for NeuroOne Medical Technologies Corporation news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on NeuroOne Medical Technologies Corporation stock.

NeuroOne Medical Technologies Corporation (symbol: NMTC) is a cutting-edge medical technology company based in Eden Prairie, Minnesota. The company specializes in the development and commercialization of innovative thin-film electrode technology designed for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, brain stimulation, and ablation solutions. These technologies are particularly beneficial for patients suffering from a variety of brain-related disorders, including epilepsy, Parkinson's disease, dystonia, and essential tremors.

NeuroOne's core business revolves around creating comprehensive neuromodulation solutions that integrate cEEG and sEEG recording, monitoring, brain stimulation, and ablation. This focus has led to notable advancements such as the Evo® sEEG system, which is the first FDA-cleared thin-film sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue, with the added benefit of temperature control.

The company is actively involved in various exciting projects and partnerships. One of their key initiatives is the Drug Delivery Program, which is expected to achieve several important milestones in the near future. Additionally, NeuroOne is continuously enhancing its product portfolio to better serve its target patient population.

Financially, NeuroOne has provided promising updates for the second quarter of the fiscal year 2024. The company’s recent business highlights include significant progress in their OneRF™ Ablation System and Spinal Cord Stimulation Program. Investors and interested parties can access more detailed financial results and updates through their quarterly conference calls and webcasts.

For more information or to get in touch with NeuroOne, please contact them at 800-631-4030 or email ir@nmtc1.com.

Rhea-AI Summary

NeuroOne announced that the CMS has approved a new ICD-10-PCS code for its OneRF™ Ablation procedure, effective October 1, 2024. This code, 00503Z4, facilitates hospital reporting of inpatient procedures using the FDA-cleared OneRF™ Ablation system, aimed at creating RF lesions for neurosurgical operations. CEO Dave Rosa highlighted that this approval is key to increasing the recognition and utilization of their technology, potentially reducing hospital stays and adverse events. NeuroOne's product portfolio includes the Evo® cortical and sEEG electrode lines for brain mapping and RF ablation, with the brain ablation market estimated to exceed $100M globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
-
Rhea-AI Summary

NeuroOne Medical Technologies (NASDAQ: NMTC) reported its financial results for Q2 FY2024, ending March 31, 2024. Product revenue increased to $1,377,000 from $466,000 in Q2 FY2023. The company raised an additional $2 million through the ATM Program. Key product updates include the commercial launch of the OneRF Ablation System and expanded use of the Evo sEEG system by Zimmer Biomet.

R&D expenses decreased to $1.3 million, while SG&A expenses rose to $2 million. Total operating expenses were $3.3 million. The net loss dropped to $2.9 million from $3.5 million in Q2 FY2023. Cash and cash equivalents fell to $2.4 million from $5.3 million as of September 2023.

Key upcoming milestones include transitioning to OneRF electrodes, enhancing the drug delivery program, and refining the spinal cord stimulation program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
-
Rhea-AI Summary

NeuroOne Medical Technologies (NMTC) will host a conference call and webcast on May 14, 2024, to discuss the financial results for its second quarter of fiscal year 2024 and provide a corporate update. The company focuses on improving surgical care options and outcomes for patients with neurological disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
conferences earnings
Rhea-AI Summary
NeuroOne Medical Technologies (NMTC) CEO Dave Rosa appeared on Bloomberg Technology to discuss the Company's latest developments in improving surgical care options for patients with neurological disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
-
Rhea-AI Summary
NeuroOne Medical Technologies announced the first implant of its OneRF™ Ablation electrode, a FDA-cleared thin-film, sEEG-guided RF system capable of recording electrical activity and ablating nervous tissue with temperature control. The system offers new treatment options for patients with neurological disorders, positioning the company as a market leader in multi-functional diagnostic and therapeutic electrode technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
none
-
Rhea-AI Summary
NeuroOne Medical Technologies (NMTC) CEO, Dave Rosa, appeared on Fox Business Network's Varney & Co. to discuss the company's new diagnostic and therapeutic device. The device aims to improve patient outcomes by reducing hospitalizations and surgical procedures, thus lowering costs. NeuroOne also achieved a milestone with the commercial launch of its OneRF™ Ablation System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
Rhea-AI Summary
NeuroOne Medical Technologies announces the initiation of a commercial launch of its FDA-cleared OneRF™ Ablation System, the first thin-film electrode technology capable of recording electrical activity and ablating nervous tissue with temperature control. The system aims to improve surgical care options and outcomes for patients with neurological disorders, offering potential clinical benefits and reducing hospital stays and adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
none
-
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) will participate in the 36th Annual Roth Conference to engage with investors and analysts. The company's CEO and CFO will host meetings to discuss its medical technology solutions. The event will take place in Dana Point, California, offering networking opportunities for institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
conferences
-
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) announces an equity award under the Inducement Plan to a new employee, granting 65,000 shares at $1.07 per share. The award vests over ten years, with 25% vesting after one year and the rest quarterly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.41%
Tags
none
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) reports strong financial results for Q1 FY 2024, with product revenue of $978,000, a significant increase from $115,000 in Q1 FY 2023. The company raised $2.8 million through an ATM Offering and received FDA clearance for its OneRF™ Ablation System. The CEO highlighted positive customer feedback for Evo® sEEG and strategic advancements in other programs. Despite the net loss of $3.3 million, the company remains optimistic about future milestones and commercial launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.4%
Tags

FAQ

What is the current stock price of NeuroOne Medical Technologies Corporation (NMTC)?

The current stock price of NeuroOne Medical Technologies Corporation (NMTC) is $0.7288 as of November 20, 2024.

What is the market cap of NeuroOne Medical Technologies Corporation (NMTC)?

The market cap of NeuroOne Medical Technologies Corporation (NMTC) is approximately 22.2M.

What does NeuroOne Medical Technologies Corporation focus on?

NeuroOne focuses on developing and commercializing thin-film electrode technology for cEEG and sEEG recording, brain stimulation, and ablation solutions.

Where is NeuroOne Medical Technologies Corporation based?

The company is based in Eden Prairie, Minnesota.

What disorders does NeuroOne's technology address?

Their technology addresses brain-related disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors.

What is the Evo® sEEG system?

The Evo® sEEG system is an FDA-cleared thin-film sEEG-guided RF system that can record electrical activity and ablate nervous tissue with temperature control.

What are some of NeuroOne's current projects?

Current projects include the Drug Delivery Program and the OneRF™ Ablation System, among others.

How can I contact NeuroOne Medical Technologies Corporation?

You can contact them at 800-631-4030 or email ir@nmtc1.com.

What recent financial updates has NeuroOne provided?

In the second quarter of fiscal year 2024, NeuroOne reported progress in the OneRF™ Ablation System and Spinal Cord Stimulation Program.

What type of medical technology does NeuroOne specialize in?

NeuroOne specializes in neuromodulation technology, particularly thin-film electrode technology for cEEG and sEEG recording, brain stimulation, and ablation.

What is the significance of the FDA clearance for NeuroOne's technology?

The FDA clearance for the Evo® sEEG system signifies the approval and safety of the technology for medical use, affirming its efficacy in recording electrical activity and ablating nervous tissue.

Where can I find more detailed financial results and updates about NeuroOne?

Detailed financial results and updates can be accessed through quarterly conference calls and webcasts organized by the company.

NeuroOne Medical Technologies Corporation

Nasdaq:NMTC

NMTC Rankings

NMTC Stock Data

22.18M
27.38M
10.19%
19.46%
0.4%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
EDEN PRAIRIE